Article

Nutritional supplements may have future in treating patients with tear dysfunction

Nutritional supplements seem to make sense in the treatment of tear dysfunction, according to Marian Macsai, MD. Dr. Macsai tempered her assertion with the observation that no objective trials have been performed to support the use of nutritional supplements in patients with tear deficiency.

Nutritional supplements seem to make sense in the treatment of tear dysfunction, according toMarian Macsai, MD. Dr. Macsai tempered her assertion with the observation that no objectivetrials have been performed to support the use of nutritional supplements in patients with teardeficiency.

Dry eye disease has an underlying inflammatory component that results in decreased aqueous tearproduction and increased evaporative tear loss. Fatty acid metabolism is a hot topic in thisregard because omega 3 metabolizes into anti-inflammatory eicosanoids and thrombolytic agents,and omega 6 metabolism is key in the production of arachadonic acid and other inflammatorymediators and platelet aggregators. A shift in the omega 3:omega 6 fatty acids ratio to 2.3:1from the average American ratio of 10:1, toward omega 3 can lower the overall inflammatorystate in the body and a decreased risk of clinically diagnosed dry eye, according to Dr.Macsai, professor and vice chairwoman, Department of Ophthalmology, Northwestern University,Glenview, IL.

"The risk of dry eye decreased by about 30% per additional gram of omega 3 consumed per day inthe Women's Health Study," she said. In addition, omega-3 supplementation has a positive effecton asthma, cardiovascular disease, arthritis, depression, and adult-onset diabetes.

Flaxseed oil, which belongs to omega-3 fatty acids, is believed to reduce inflammation byinhibiting tumor necrosis factor-alpha and interleukin-1 beta. Supplementation with fish oil,another hot topic, inhibits the omega 6 pathway. Dr. Macsai pointed out that treating patientswith Sjögren's syndrome with flaxseed oil, fish oil, and vitamin E significantly improved dryeye and dry mouth symptoms. However, bilberry and evening primrose oil seem to have nosignificant effects in patients with dry eye.

"Nutritional supplementation probably should be used in patients with dry eye. Vitamin E may ormay not be needed. Theoretically, this supplementation makes sense," Dr. Macsai said. She notedthat the coagulation effect of those nutritional supplements must be kept in mind, however,especially for patients who are undergoing elective surgery. There has been no objectiveplacebo-control trial conducted to support their use.

In addition, subjection symptoms of dry eye may be related to underlying depression resultingfrom dry eye. Another consideration is that in patients who have undergone gastric bypasssurgery, these nutrients will not be absorbed.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
Alex Hacopian, MD, discusses a presbyopia-correcting IOL at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.